Brain Amyloid PET-CT Services Now Offered for Alzheimer’s Diagnostic Evaluation

Amyloid PET-CT imaging is emerging as a powerful tool in the evaluation of Alzheimer’s disease and other causes of cognitive decline. This article explains what the test reveals, who may benefit from it, and how it can influence diagnosis and care decisions.

Diagnosing Alzheimer’s disease (AD) is notoriously challenging because there is no single definitive test. Clinical assessment typically involves a combination of patient history, cognitive exams, physical and neurological evaluation, and standard imaging techniques such as MRI or CT.

Now, a more advanced imaging test — Amyloid PET‑CT — has become available for patients undergoing evaluation for Alzheimer’s disease and other causes of cognitive decline, offering deeper insight into one of the hallmark pathological features of AD. Recent communications from leading imaging centers highlight its growing clinical availability and utility.

What is Amyloid PET-CT and How Does It Work

PET-CT combines two imaging techniques — Positron Emission Tomography (PET) and Computed Tomography (CT) — into a single session. PET provides functional imaging by showing biochemical activity in the brain, while CT offers detailed anatomical structure. Together, they produce a co-registered image that reveals not only the brain’s structure but also molecular abnormalities.
In Amyloid PET-CT, a small amount of a safe radioactive tracer (e.g. compounds that bind to beta-amyloid) is injected into the patient’s bloodstream. The tracer accumulates in regions where beta-amyloid neuritic plaques — a key pathological hallmark of AD — are present. The PET scan visualizes these deposits in living patients.
This ability to “light up” amyloid plaques in a living brain was not possible with conventional imaging; previously, such plaques could only be confirmed postmortem.

What Test Results Mean: Positive vs. Negative

When the scan is interpreted, results are typically reported as either positive or negative, based on a binary visual read. Many centers use quantitative standardized metrics through specialized software to support this decision, improving confidence in the interpretation.

Negative scan: Indicates no or only sparse amyloid neuritic plaques. This suggests that Alzheimer’s disease is unlikely to be the cause of the patient’s cognitive impairment at the time of imaging. For patients, a negative result may redirect evaluation toward other possible causes of cognitive decline — potentially avoiding unnecessary Alzheimer-specific treatments.
Positive scan: Indicates moderate to abundant amyloid neuritic plaques — a pattern frequently observed in Alzheimer’s disease. However, it is important to note that amyloid accumulation can also be seen in older individuals with normal cognition or in people with other neurologic conditions. As such, a positive PET-CT is not a definitive diagnosis of Alzheimer’s disease by itself. Rather, it raises the probability and increases diagnostic confidence when combined with clinical evaluation.

Who Should Consider Amyloid PET-CT

Amyloid PET-CT is most appropriate when the result will meaningfully influence patient diagnosis or management. According to updated clinical guidance, candidates include:

Adults with cognitive impairment in whom Alzheimer’s disease is suspected, but standard evaluations (clinical exam, MRI, cognitive testing, lab tests) remain inconclusive.
Individuals concerned about memory loss who want clarification about whether amyloid plaques are present — especially those considering future anti-amyloid therapy.
Patients whose neurological work-up has already included neurological exams, cognitive assessments, lab work, and structural imaging (e.g. MRI), and where biomarker-based clarification is desired.

Referrals typically come from neurologists or dementia specialists, though primary care providers might also request the test when clinically justified.

Moreover, with the recent emergence of anti-amyloid treatments (for early/mild AD), confirmed amyloid positivity has become an important consideration for therapy eligibility.

Clinical Benefits: Why Amyloid PET-CT Matters

Amyloid PET-CT offers several potential advantages that can improve patient care and reduce uncertainty:

Improved diagnostic accuracy and confidence: The scan can clarify ambiguous cases where diagnosis based solely on symptoms and MRI is uncertain. As per clinical studies, amyloid PET markedly improves diagnostic certainty in dementia assessments.
Better care planning & management: A clearer diagnosis helps clinicians and families make more informed decisions regarding care, lifestyle, monitoring, and potential treatments — especially if amyloid-targeting therapies are considered.
Avoiding unnecessary or potentially harmful treatments: If amyloid is absent, clinicians may avoid administering Alzheimer’s-specific therapies that could worsen symptoms if misapplied. This is particularly relevant because some dementia symptoms may arise from other causes.
Non-invasive alternative to lumbar puncture: While cerebrospinal fluid (CSF) biomarkers are another way to assess amyloid, obtaining CSF requires a lumbar puncture — an invasive procedure. Amyloid PET-CT offers a non-invasive alternative.

Despite its benefits, Amyloid PET-CT is not without limitations — and results must be interpreted with caution:

Not entirely definitive: A positive scan does not guarantee that a person has Alzheimer’s disease. Amyloid plaques can accumulate in people without cognitive symptoms or in those with other neurological disorders (e.g. vascular dementia, diffuse Lewy body disease, cerebral amyloid angiopathy).
Access and cost: The availability of PET-CT scanners, short half-life of tracers, and cost can limit use — especially in developing countries or regions where nuclear imaging infrastructure is not widely available.
Radiation exposure: As with any PET-CT, there is exposure to ionizing radiation. While generally considered safe for diagnostic purposes, it remains a trade-off to consider — especially for repeated scans.
Need for comprehensive evaluation: Amyloid PET-CT should not replace clinical exams, cognitive assessments, and structural neuroimaging; rather, it should complement them as part of a broader diagnostic work-up.

What This Means for Patients and Families

For patients and families grappling with memory loss or unclear cognitive decline, the availability of Amyloid PET-CT offers an opportunity for better clarity and earlier intervention. Confirming whether amyloid plaques are present can guide both prognosis and decisions about therapy, lifestyle planning, and care.

Because Alzheimer’s can progress slowly and remain difficult to distinguish from other forms of dementia or cognitive impairment — particularly in early stages — this imaging tool adds a valuable layer of precision.

References

Brain Amyloid PET-CT Services Now Offered for Alzheimer’s Diagnostic Evaluation – Mid West Medical Edition – (Accessed on Nov 27, 2025)
Brain amyloid PET-CT is now available for patients being evaluated for Alzheimer’s disease – Nebraska medicine – (Accessed on Nov 27, 2025)
Understanding Alzheimer’s Disease and How Amyloid PET/CT Imaging Can Help – AMI -(Accessed on Nov 27, 2025)
https://radiology.ucsf.edu/patient-care/services/specialty-imaging/alzheimer – UCSF – (Accessed on Nov 27, 2025)

Possible References Used